2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts

Viking Therapeutics (NASDAQ: VKTX) and Regeneron Pharmaceuticals (NASDAQ: REGN) have faced challenges this year that have sunk their stock prices. The former is down by 37% this year, while the latter has declined 17%.Could this be an excellent opportunity for investors to scoop up shares of these companies on the dip? That's the case if they're likely to rebound. And some Wall Street analysts think that could be in the cards. Viking's average price target of $88.78 implies an upside of 245% from its current levels, while Regeneron's $716.18 implies it could jump by 21%.Let's see whether Viking and Regeneron really could deliver solid returns in the next year or so.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool